Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
Details are scant about the “unexplained illness” seen with Johnson & Johnson’s Covid-19 vaccine, but the news puts another dent in public confidence.
Pfizer/Biontech’s preprint might prove academic as investors look to pivotal study designs and readouts.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.